CN115023135A - 冷冻保存剂与使用其的线粒体冷冻保存方法 - Google Patents
冷冻保存剂与使用其的线粒体冷冻保存方法 Download PDFInfo
- Publication number
- CN115023135A CN115023135A CN202080094514.1A CN202080094514A CN115023135A CN 115023135 A CN115023135 A CN 115023135A CN 202080094514 A CN202080094514 A CN 202080094514A CN 115023135 A CN115023135 A CN 115023135A
- Authority
- CN
- China
- Prior art keywords
- mitochondria
- cryopreservation
- cryopreservative
- cryopreservation agent
- trehalose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000005138 cryopreservation Methods 0.000 title claims abstract description 87
- 238000000034 method Methods 0.000 title claims description 24
- 230000002438 mitochondrial effect Effects 0.000 title claims description 24
- 210000003470 mitochondria Anatomy 0.000 claims abstract description 113
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 51
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 28
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 24
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 24
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 24
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 20
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 20
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 18
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims abstract description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 12
- 239000001103 potassium chloride Substances 0.000 claims abstract description 12
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 12
- 239000011780 sodium chloride Substances 0.000 claims abstract description 6
- 230000002338 cryopreservative effect Effects 0.000 claims description 61
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 229960001484 edetic acid Drugs 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 238000007710 freezing Methods 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 239000013618 particulate matter Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 abstract description 17
- 239000007995 HEPES buffer Substances 0.000 abstract description 16
- 230000000052 comparative effect Effects 0.000 description 24
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 18
- 230000036284 oxygen consumption Effects 0.000 description 15
- 238000010257 thawing Methods 0.000 description 14
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 11
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000001700 mitochondrial membrane Anatomy 0.000 description 7
- 238000000635 electron micrograph Methods 0.000 description 6
- 230000027721 electron transport chain Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000000971 hippocampal effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- ZKVXBFFGNSPEGE-UHFFFAOYSA-N OC=CN1CCN(CC1)CCS(=O)(=O)O Chemical compound OC=CN1CCN(CC1)CCS(=O)(=O)O ZKVXBFFGNSPEGE-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 2
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 2
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 2
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 2
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 229940119213 Adenosinetriphosphate synthase inhibitor Drugs 0.000 description 2
- 229930182536 Antimycin Natural products 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical group FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 101000693913 Homo sapiens Albumin Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 2
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 102000044814 human ALB Human genes 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229930191479 oligomycin Natural products 0.000 description 2
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000000164 protein isolation Methods 0.000 description 2
- 229940080817 rotenone Drugs 0.000 description 2
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- -1 4- (2-hydroxyethenyl) -1-piperazinesulfonic acid Chemical compound 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008965 mitochondrial swelling Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/42—Low-temperature sample treatment, e.g. cryofixation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
一种冷冻保存剂，包含海藻糖、HEPES以及人类血清白蛋白，且此冷冻保存剂不包含氯化钾、氯化钠、乙二醇、乙二醇四乙酸以及乙二胺四乙酸。前述冷冻保存剂可用于线粒体的冷冻保存。
Description
PCT国内申请，说明书已公开。
Claims (10)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/077063 WO2021168764A1 (zh) | 2020-02-28 | 2020-02-28 | 冷冻保存剂与使用其的线粒体冷冻保存方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115023135A true CN115023135A (zh) | 2022-09-06 |
| CN115023135B CN115023135B (zh) | 2024-04-19 |
Family
ID=77489775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080094514.1A Active CN115023135B (zh) | 2020-02-28 | 2020-02-28 | 线粒体的冷冻保存剂与使用其的线粒体冷冻保存方法 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20230003625A1 (zh) |
| CN (1) | CN115023135B (zh) |
| WO (1) | WO2021168764A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102665782B1 (ko) | 2022-03-29 | 2024-05-14 | 주식회사 파이안바이오테크놀로지 | 동결 및 동결건조된 미토콘드리아 및 이의 용도 |
| WO2023237789A1 (en) | 2022-06-10 | 2023-12-14 | Cellvie Ag | Composition and method for cryopreservation of mitochondria |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108739796A (zh) * | 2018-06-05 | 2018-11-06 | 瑞柏生物（中国）股份有限公司 | 一种玻璃化冷冻液及其制备方法 |
| CN109789200A (zh) * | 2016-08-03 | 2019-05-21 | 武田疫苗股份有限公司 | 用改善的配制剂使黄病毒稳定化的组合物和方法 |
| CN110072992A (zh) * | 2016-12-14 | 2019-07-30 | 株式会社大塚制药工场 | 哺乳动物细胞冷冻保存液 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040185524A1 (en) * | 2000-02-10 | 2004-09-23 | Crowe John H. | Biological samples and method for increasing survival of biological samples |
| TWI766137B (zh) * | 2018-12-24 | 2022-06-01 | 台灣粒線體應用技術股份有限公司 | 冷凍保存劑與使用其的粒線體冷凍保存方法 |
| CN110684817B (zh) * | 2019-10-23 | 2021-07-20 | 北京赛科希德科技股份有限公司 | 人纤维蛋白体外降解方法 |
-
2020
- 2020-02-28 CN CN202080094514.1A patent/CN115023135B/zh active Active
- 2020-02-28 WO PCT/CN2020/077063 patent/WO2021168764A1/zh active Application Filing
-
2022
- 2022-08-26 US US17/897,011 patent/US20230003625A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109789200A (zh) * | 2016-08-03 | 2019-05-21 | 武田疫苗股份有限公司 | 用改善的配制剂使黄病毒稳定化的组合物和方法 |
| CN110072992A (zh) * | 2016-12-14 | 2019-07-30 | 株式会社大塚制药工场 | 哺乳动物细胞冷冻保存液 |
| CN108739796A (zh) * | 2018-06-05 | 2018-11-06 | 瑞柏生物（中国）股份有限公司 | 一种玻璃化冷冻液及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| YAMAGUCHI R ET AL,: "Mitochondria frozen with trehalose retain a number of biological functions and preserve outer membrane integrity", CELL DEATH DIFFER * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021168764A1 (zh) | 2021-09-02 |
| CN115023135B (zh) | 2024-04-19 |
| US20230003625A1 (en) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104663649B (zh) | 人类卵母细胞冷冻保护剂 | |
| Üstüner et al. | Effect of egg yolk and soybean lecithin on tris-based extender in post-thaw ram semen quality and in vitro fertility | |
| JP6879949B2 (ja) | 治療目的のための細胞の凍結保存方法 | |
| EP2885969A1 (en) | Cryopreservation tools and methods | |
| KR20070007836A (ko) | 동결보존 배지 | |
| EP2934110B1 (en) | Use of connexin channel inhibitors to protect grafts | |
| CA2719806A1 (en) | Method, system, and apparatus for hypothermic collection, storage, transport and banking of birth tissue | |
| Alcay et al. | Effects of low molecular weight cryoprotectants on the post-thaw ram sperm quality and fertilizing ability | |
| Reed et al. | Soy lecithin replaces egg yolk for cryopreservation of human sperm without adversely affecting postthaw motility, morphology, sperm DNA integrity, or sperm binding to hyaluronate | |
| CN115023135A (zh) | 冷冻保存剂与使用其的线粒体冷冻保存方法 | |
| EP3501278B1 (en) | Composition for cryopreservation of bovine reproductive cells and cryopreservation method therefor | |
| EP2639298B1 (en) | The method for preparing human semen for in vitro fertilization or for artificial insemination | |
| TWI766137B (zh) | 冷凍保存劑與使用其的粒線體冷凍保存方法 | |
| Gomes-Alves et al. | Use of commercial extenders and alternatives to prevent sperm agglutination for cryopreservation of brown bear semen | |
| RU2678106C2 (ru) | Способ витрификации овариальной ткани | |
| TWI836467B (zh) | 冷凍保存劑及其用途 | |
| Maltaris et al. | Simple prediction of the survival of follicles in cryopreserved human ovarian tissue | |
| TW202236961A (zh) | 冷凍保存劑的用途與粒線體冷凍保存方法 | |
| Hu et al. | Current status of Male fertility preservation in humans | |
| JP6838232B2 (ja) | 精液用保存液、及びそれを用いた精液輸送方法 | |
| Fakhrildin et al. | Effect of two types and two concentrations of cryoprotectants on ovine oocytes morphology and viability post-vitrification | |
| Jeamanukoolkit et al. | Comparison of the Motility, Morphology, and DNA Integrity of Cryopreserved Human Spermatozoa from Processing Semen before and after Cryopreservation. | |
| Hinting et al. | Recent updates of sperm cryopreservation technique: a literature review | |
| Monteiro et al. | Fertility of epididymal cauda sperm from subfertile stallions/Fertilidade de espermatozoides recuperados da cauda do epididimo de garanhoes subferteis/La fertilidad de espermatozoides recuperados de la cola del epididimo de garanones subfertiles | |
| Bathgate et al. | Effects of platelet-activating factor and platelet-activating factor: acetylhydrolase on in vitro post-thaw boar sperm parameters |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |